Global Gene Therapy Market Size, Trends, and Growth Opportunity, By Vector Type (Viral Vector and Non-Viral Vector), Method (Ex-Vivo and In-Vivo), Application (Rare Diseases, Neurological Disorders, Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, and Other Diseases), End User (Cancer Institutes, Research institutes, Hospitals, and Others) By Region and forecast till 2030.

Report ID : AMR1004286 | Industries : Healthcare | Published On :December 2023 | Page Count : 215

Global Gene Therapy Market Size, Trends, and Growth Opportunity, By Vector Type (Viral Vector and Non-Viral Vector), Method (Ex-Vivo and In-Vivo), Application (Rare Diseases, Neurological Disorders, Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, and Other Diseases), End User (Cancer Institutes, Research institutes, Hospitals, and Others) By Region and forecast till 2030.

Global Gene Therapy Market

Global Gene Therapy Market was valued at USD 8.49 billion in 2022 and is slated to reach USD 29.52 billion by 2030 at a CAGR of 16.85% from 2023-2030.
A medical approach called gene therapy targets the underlying genetic problem to treat or prevent disease. By altering a person's genetic makeup, gene therapy methods enable doctors to address an issue without using medications or surgery. Gene therapy is being used to treat a select few conditions, such as the muscle disorder spinal muscular atrophy and the eye disorder Leber congenital amaurosis. Numerous different gene therapies are being researched to make sure they are reliable and effective. The promising method of genome editing is short to be used by medical practitioners to treat human ailments. The most crucial requirement for the success of gene therapy is the ability to successfully transport a therapeutic gene to a target cell. That gene must then be delivered to the cell wall's nucleus, where it will act as a template for building protein molecules. The protein then produces the main therapeutic effect.

Market Drivers
Ailments that previously only received temporary therapies now have permanent remedies because of gene therapy. Gene therapy failed for a very long time; nevertheless, in recent years, successful and long-lasting treated instances have been documented. Promising results have been reached for a wide range of genetic ailments, including blood abnormalities, immunological inadequacies, eyesight problems, nerve cell regeneration, metabolic disorders, and several cancer kinds. Gene therapy has the potential to be a personalized treatment that can "cure" a range of diseases with more specificity and fewer negative effects. Gene therapy is the practice of transferring genetic material to a patient to treat an ailment or, at the very least, improve their clinical condition. One way that gene therapy works is by using viruses as genetic carriers to transfer the desired gene to the target cells. Depending on the kind of genome they contain, these vectors are categorized as either RNA-based or DNA-based viral vectors.
In numerous countries in the Region, genetic and congenital illnesses account for a considerable portion of pregnancy and neonatal mortality. Genetic factors frequently have a role in the development of several complex diseases. Numerous genetic disorders are caused by gene variations, which are essentially present in every cell in the body. As a result, these disorders typically affect a variety of bodily systems, and the majority of them are incurable.

Market Restraints
Gene therapy is a novel branch of medicine that includes adding, erasing, or altering genetic material in a patient's genome to treat a disease. Gene therapy, though still in its infancy, has already demonstrated significant promise for the treatment and even cure of previously incurable diseases. In many countries, the cost of gene therapy is still very loosely regulated and decided on an individual basis, typically centered around a single upfront payment.

Covid-19 Impact
The COVID-19 epidemic has brought to light the necessity for gene therapy and other cutting-edge medical procedures. As a result of the virus's considerable effects on the respiratory system, there is now a greater need for gene treatments to treat respiratory disorders. Furthermore, COVID-19 has illustrated the value of funding R&D for cutting-edge treatments, such as gene therapies. The funding of research and development for gene therapy has also been impacted by the COVID-19 pandemic. Due to the pandemic's negative economic effects, many businesses have had to reduce their research expenditures, and investors are now more hesitant to engage in early-stage biotech firms.

Recent Development
The FDA approved Adstiladrin (nadofaragene firadenovec-vncg), a novel adenovirus vector-based gene therapy, for the treatment of adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors, according to Ferring Pharmaceuticals' announcement in December. This has aided the business in diversifying its product line.
For adult patients with relapsed or refractory follicular lymphoma following two or more lines of systemic therapy, Novartis AG (Switzerland) received FDA approval for KYMRIAH in May 2022.

Market Segmentation
The global Gene Therapy Market is segmented into By Vector Type, Method, Application, and End User. By Vector Types such as Viral Vector and Non-Viral Vector. By Methods such as Ex-Vivo and In-Vivo. By Application such as Rare Diseases, Neurological Disorders, Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, and Other Diseases. By End Users such as Cancer Institutes, Research institutes, Hospitals, and Others.

Regional Analysis
The global Gene Therapy Market is segmented into five regions Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market is dominated by North America, where rising R&D expenditures are anticipated to fuel market expansion. Due to the prominence of significant players Novartis AG and Kite Pharma, the U.S. dominates the North American region. Due to its extensive expansion, mass production of products used in gene therapy, and rising demand from developing markets, Germany dominates the continent of Europe. Due to rising consumer preferences for less invasive medical procedures, China currently controls the majority of the Asia-Pacific market.

Key Players
This report includes a list of numerous Key Players, Novartis AG, Enzyvant Therapeutics GmbHAudubon Bioscience, Kite Pharma (a subsidiary of Gilead Sciences, Inc.), Oxford Biomedica, Amgen Inc., AnGes, Inc., bluebird bio, Inc., Shanghai Sunway Biotech Co. Ltd., Dendreon Pharmaceuticals LLC., and Spark Therapeutics, Inc.

Market Taxonomy
By Vector Type
• Viral Vector
• Non-Viral Vector
By Method
• Ex-Vivo
• In-Vivo
By Application
• Oncological Disorders
• Cardiovascular Diseases
• Infectious Disease
• Rare Diseases
• Neurological Disorders
• Other Diseases
By End User
• Cancer Institutes
• Hospitals
• Research Institutes
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Latin America
o Brazil
o Argentina
o Colombia
o Peru
o Chile
o Venezuela
o Rest of Latin America
• Europe
o Germany
o France
o UK
o Russia
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o New Zealand
o Singapore
o Malaysia
o Rest of Asia Pacific
• Middle East & Africa
o Saudi Arabia
o UAE
o Egypt
o Kuwait
o South Africa
o Rest Middle East & Africa

Global Gene Therapy Market

1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Gene Therapy Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn.
4.2.6 Post covid-19 world Supply& Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Gene Therapy Market, By Vector Type
5.1 Y-o-Y Growth Comparison, By Vector Type
5.2 Global Gene Therapy Market Share Analysis, By Vector Type
5.3 Global Gene Therapy Market Size and Forecast, By Vector Type
5.3.1 Viral Vector
5.3.2 Non-Viral Vector
6 Global Gene Therapy Market, By Application
6.1 Y-o-Y Growth Comparison, By Application
6.2 Global Gene Therapy Market Share Analysis, By Application
6.3 Global Gene Therapy Market Size and Forecast, By Application
6.3.1 Oncological Disorders
6.3.2 Cardiovascular Diseases
6.3.3 Infectious Disease
6.3.4 Rare Diseases
6.3.5 Neurological Disorders
6.3.6 Other Diseases
7 Global Gene Therapy Market, By Method
7.1 Y-o-Y Growth Comparison, By Method
7.2 Global Gene Therapy Market Share Analysis, By Method
7.3 Global Gene Therapy Market Size and Forecast, By Method
7.3.1 Ex-Vivo
7.3.2 In-Vivo
8 Global Gene Therapy Market, By End User
8.1 Y-o-Y Growth Comparison, By End User
8.2 Global Gene Therapy Market Share Analysis, By End User
8.3 Global Gene Therapy Market Size and Forecast, By End User
8.3.1 Cancer Institutes
8.3.2 Hospitals
8.3.3 Research Institutes
8.3.4 Others
9 Global Gene Therapy Market, By Region
9.1 Global Gene Therapy Market Share Analysis, By Region
9.2 Global Gene Therapy Market Size and Forecast, By Region
9.3 Global Gene Therapy Market Trends and Forecast, By Region
10 North America Gene Therapy Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 North America Gene Therapy Market Share Analysis, By Vector Type
10.3 North America Gene Therapy Market Size and Forecast, By Application
10.4 North America Gene Therapy Market Size and Forecast, By Method
10.5 North America Gene Therapy Market Size and Forecast, By End User
10.6 North America Gene Therapy Market Size and Forecast, By Country
10.6.1 U.S.
10.6.1.1. Market Size and Forecast, By Vector Type
10.6.1.2 Market Size and Forecast, By Application
10.6.1.3. Market Size and Forecast, By Method
10.6.1.4. Market Size and Forecast, By End User
10.6.2 Canada
10.6.2.1. Market Size and Forecast, By Vector Type
10.6.2.2 Market Size and Forecast, By Application
10.6.2.3. Market Size and Forecast, By Method
10.6.2.4 Market Size and Forecast, By End User
10.6.3 Mexico
10.6.3.1. Market Size and Forecast, By Vector Type
10.6.3.2 Market Size and Forecast, By Application
10.6.3.3. Market Size and Forecast, By Method
11 Europe Gene Therapy Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Europe Gene Therapy Market Share Analysis, By Vector Type
11.3 Europe Gene Therapy Market Size and Forecast, By Application
11.4 Europe Gene Therapy Market Size and Forecast, By Method
11.5 Europe Gene Therapy Market Size and Forecast, By End User
11.6 Europe Gene Therapy Market Size and Forecast, By Country
11.6.1 Germany
11.6.1.1. Market Size and Forecast, By Vector Type
11.6.1.2 Market Size and Forecast, By Application
11.6.1.3. Market Size and Forecast, By Method
11.6.1.4. Market Size and Forecast, By End User
11.6.2 France
11.6.2.1. Market Size and Forecast, By Vector Type
11.6.2.2 Market Size and Forecast, By Application
11.6.2.3. Market Size and Forecast, By Method
11.6.2.4 Market Size and Forecast, By End User
11.6.3 UK
11.6.3.1. Market Size and Forecast, By Vector Type
11.6.3.2 Market Size and Forecast, By Application
11.6.3.3. Market Size and Forecast, By Method
11.6.3.4 Market Size and Forecast, By End User
11.6.4. Russia
11.6.4.1. Market Size and Forecast, By Vector Type
11.6.4.2 Market Size and Forecast, By Application
11.6.4.3. Market Size and Forecast, By Method
11.6.4.4 Market Size and Forecast, By End User
11.6.5. Italy
11.6.5.1. Market Size and Forecast, By Vector Type
11.6.5.2 Market Size and Forecast, By Application
11.6.5.3. Market Size and Forecast, By Method
11.6.5.4. Market Size and Forecast, By End User
11.6.6. Spain
11.6.6.1. Market Size and Forecast, By Vector Type
11.6.6.2 Market Size and Forecast, By Application
11.6.6.3. Market Size and Forecast, By Method
11.6.6.4. Market Size and Forecast, By End User
11.6.7. Rest of Europe
11.6.7.1. Market Size and Forecast, By Vector Type
11.6.7.2 Market Size and Forecast, By Application
11.6.7.3. Market Size and Forecast, By Method
11.6.7.4. Market Size and Forecast, By End User
12 Asia Pacific Gene Therapy Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Asia Pacific Gene Therapy Market Share Analysis, By Vector Type
12.3 Asia Pacific Gene Therapy Market Size and Forecast, By Application
12.4 Asia Pacific Gene Therapy Market Size and Forecast, By Method
12.5 Asia Pacific Gene Therapy Market Size and Forecast, By End User
12.6 Asia Pacific Gene Therapy Market Size and Forecast, By Country
12.6.1 China
12.6.1.1. Market Size and Forecast, By Vector Type
12.6.1.2 Market Size and Forecast, By Application
12.6.1.3. Market Size and Forecast, By Method
12.6.1.4. Market Size and Forecast, By End User
12.6.2 Japan
12.6.2.1. Market Size and Forecast, By Vector Type
12.6.2.2 Market Size and Forecast, By Application
12.6.2.3. Market Size and Forecast, By Method
12.6.2.4. Market Size and Forecast, By End User
12.6.3 India
12.6.3.1. Market Size and Forecast, By Vector Type
12.6.3.2 Market Size and Forecast, By Application
12.6.3.3. Market Size and Forecast, By Method
12.6.3.4. Market Size and Forecast, By End User
12.6.4. South Korea
12.6.4.1. Market Size and Forecast, By Vector Type
12.6.4.2 Market Size and Forecast, By Application
12.6.4.3. Market Size and Forecast, By Method
12.6.4.4. Market Size and Forecast, By End User
12.6.5. Australia
12.6.5.1. Market Size and Forecast, By Vector Type
12.6.5.2 Market Size and Forecast, By Application
12.6.5.3. Market Size and Forecast, By Method
12.6.5.4 Market Size and Forecast, By End User
12.6.6. New Zealand
12.6.6.1. Market Size and Forecast, By Vector Type
12.6.6.2 Market Size and Forecast, By Application
12.6.6.3. Market Size and Forecast, By Method
12.6.6.4. Market Size and Forecast, By End User
12.6.7. Singapore
12.6.7.1. Market Size and Forecast, By Vector Type
12.6.7.2 Market Size and Forecast, By Application
12.6.7.3. Market Size and Forecast, By Method
12.6.7.4. Market Size and Forecast, By End User
12.6.8. Malaysia
12.6.8.1. Market Size and Forecast, By Vector Type
12.6.8.2 Market Size and Forecast, By Application
12.6.8.3. Market Size and Forecast, By Method
12.6.8.4. Market Size and Forecast, By End User
12.6.9. Rest of Asia
12.6.9.1. Market Size and Forecast, By Vector Type
12.6.9.2 Market Size and Forecast, By Application
12.6.9.3. Market Size and Forecast, By Method
12.6.9.4. Market Size and Forecast, By End User
13 Latin America Gene Therapy Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Latin America Gene Therapy Market Share Analysis, By Vector Type
13.3 Latin America Gene Therapy Market Size and Forecast, By Application
13.4 Latin America Gene Therapy Market Size and Forecast, By Method
13.5 Latin America Gene Therapy Market Size and Forecast, By End User
13.6 Latin America Gene Therapy Market Size and Forecast, By Country
13.6.1 Brazil
13.6.1.1. Market Size and Forecast, By Vector Type
13.6.1.2 Market Size and Forecast, By Application
13.6.1.3. Market Size and Forecast, By Method
13.6.1.4. Market Size and Forecast, By End User
13.6.2 Argentina
13.6.2.1. Market Size and Forecast, By Vector Type
13.6.2.2 Market Size and Forecast, By Application
13.6.2.3. Market Size and Forecast, By Method
13.6.2.4. Market Size and Forecast, By End User
13.6.3. Colombia
13.6.3.1. Market Size and Forecast, By Vector Type
13.6.3.2 Market Size and Forecast, By Application
13.6.3.3. Market Size and Forecast, By Method
13.6.3.4. Market Size and Forecast, By End User
13.6.4. Peru
13.6.4.1. Market Size and Forecast, By Vector Type
13.6.4.2 Market Size and Forecast, By Application
13.6.4.3. Market Size and Forecast, By Method
13.6.4.4 Market Size and Forecast, By End User
13.6.5. Chile
13.6.5.1. Market Size and Forecast, By Vector Type
13.6.5.2 Market Size and Forecast, By Application
13.6.5.3. Market Size and Forecast, By Method
13.6.5.4. Market Size and Forecast, By End User
13.6.6. Venezuela
13.6.6.1. Market Size and Forecast, By Vector Type
13.6.6.2 Market Size and Forecast, By Application
13.6.6.3. Market Size and Forecast, By Method
13.6.6.4. Market Size and Forecast, By End User
13.6.7. Rest of Latin America
13.6.7.1. Market Size and Forecast, By Vector Type
13.6.7.2 Market Size and Forecast, By Application
13.6.7.3. Market Size and Forecast, By Method
13.6.7.4. Market Size and Forecast, By End User
14 Middle East Gene Therapy Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Middle East Gene Therapy Market Share Analysis, By Vector Type
14.3 Middle East Gene Therapy Market Size and Forecast, By Application
14.4 Middle East Gene Therapy Market Size and Forecast, By Method
14.5 Middle East Gene Therapy Market Size and Forecast, By End User
14.6 Middle East Gene Therapy Market Size and Forecast, By Country
14.6.1. Saudi Arabia
14.6.1.1. Market Size and Forecast, By Vector Type
14.6.1.2 Market Size and Forecast, By Application
14.6.1.3. Market Size and Forecast, By Method
14.6.1.4. Market Size and Forecast, By End User
14.6.2 UAE
14.6.2.1. Market Size and Forecast, By Vector Type
14.6.2.2 Market Size and Forecast, By Application
14.6.2.3. Market Size and Forecast, By Method
14.6.2.4. Market Size and Forecast, By End User
14.6.3 Egypt
14.6.3.1. Market Size and Forecast, By Vector Type
14.6.3.2 Market Size and Forecast, By Application
14.6.3.3. Market Size and Forecast, By Method
14.6.3.4. Market Size and Forecast, By End User
14.6.4 Kuwait
14.6.4.1. Market Size and Forecast, By Vector Type
14.6.4.2 Market Size and Forecast, By Application
14.6.4.3. Market Size and Forecast, By Method
14.6.4.4. Market Size and Forecast, By End User
14.6.5 South Africa
14.6.5.1. Market Size and Forecast, By Vector Type
14.6.5.2 Market Size and Forecast, By Application
14.6.5.3. Market Size and Forecast, By Method
14.6.5.4. Market Size and Forecast, By End User
14.6.6 Rest of Middle East & Africa
14.6.6.1. Market Size and Forecast, By Vector Type
14.6.6.2 Market Size and Forecast, By Application
14.6.6.3. Market Size and Forecast, By Method
14.6.6.4 Market Size and Forecast, By End User
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1 Novartis AG
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 Enzyvant Therapeutics GmbHAudubon Bioscience
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3. AnGes, Inc.
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Kite Pharma (a subsidiary of Gilead Sciences, Inc.)
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Oxford Biomedica
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 Amgen Inc.
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 bluebird bio, Inc.
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8 Shanghai Sunway Biotech Co. Ltd.
16.8.1 Overview
16.8.2 Offerings
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 Dendreon Pharmaceuticals LLC.
16.9.1 Overview
16.9.2 Offerings
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies
16.10 Spark Therapeutics, Inc.
16.10.1 Overview
16.10.2 Offerings
16.10.3 Key Financials
16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies